Trials / Completed
CompletedNCT02684253
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Randomized Controlled Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Nivolumab is an antibody (a type of human protein) that is designed to boost your body's immune system. It does this by allowing immune cells to grow and fight the cancer. Nivolumab has been approved by the FDA for the treatment of melanoma (a form of skin cancer) and lung cancer. It is currently under study for the treatment of head and neck squamous cell cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | |
| RADIATION | Stereotactic Body Radiation Therapy (SBRT) |
Timeline
- Start date
- 2016-02-11
- Primary completion
- 2021-01-22
- Completion
- 2021-01-22
- First posted
- 2016-02-17
- Last updated
- 2022-03-10
- Results posted
- 2022-03-10
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02684253. Inclusion in this directory is not an endorsement.